| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Wolfe Research analyst Mike Polark upgrades Edwards Lifesciences (NYSE:EW) from Underperform to Peer Perform.
Jefferies analyst Matthew Taylor upgrades Edwards Lifesciences (NYSE:EW) from Hold to Buy and raises the price target from $...
Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:EW) with a Hold and raises the price target ...
ENCIRCLE mitral trial achieves primary and secondary endpoints EVOQUE tricuspid valve registry demonstrates more favorable out...
SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven yearsEdwards...